27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Analysts at Mizuho initiated coverage on Biogen Inc (NASDAQ: BIIB) with a Neutral rating. The price target for Biogen is set to $290. Biogen shares closed at $295.62 on Monday.
- Jefferies initiated coverage on BioScrip Inc (NASDAQ: BIOS) with a Buy rating. BioScrip shares closed at $2.61 on Monday.
- Analysts at Piper Jaffray initiated coverage of Mammoth Energy Services Inc (NASDAQ: TUSK) with an Overweight rating. Mammoth Energy shares closed at $13.61 on Monday.
- Analysts at JP Morgan initiated coverage of Adient PLC (NYSE: ADNT) with a Neutral rating. The price target for Adient is set to $55. Adient shares closed at $44.60 on Monday.
- Analysts at Aegis Capital initiated coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating. The price target for Nektar Therapeutics is set to $21. Nektar Therapeutics shares closed at $12.80 on Monday.
- Mizuho initiated coverage on Amgen, Inc. (NASDAQ: AMGN) with a Buy rating. The price target for Amgen is set to $164. Amgen shares closed at $139.21 on Monday.
- Analysts at Deutsche Bank initiated coverage on Microsemi Corporation (NASDAQ: MSCC) with a Buy rating. The price target for Microsemi is set to $60. Microsemi shares closed at $47.84 on Monday.
- Analysts at Imperial Capital initiated coverage on Newcastle Investment Corp. (NYSE: NCT) with an In-Line rating. The price target for Newcastle Investment is set to $4.50. Newcastle Investment shares closed at $4.54 on Monday.
- Analysts at BMO Capital initiated coverage on Sociedad Quimica y Minera de Chile (ADR) (NYSE: SQM) with a Market Perform rating. The price target for Sociedad Quimica y Minera de Chile is set to $30. Sociedad Quimica y Minera de Chile shares closed at $29.07 on Monday.
- Mizuho initiated coverage on Celgene Corporation (NASDAQ: CELG) with a Buy rating. The price target for Celgene is set to $130. Celgene shares closed at $107.49 on Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!